SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kumaran Mudaliar, Michael T. Tetzlaff, Madeleine Duvic, Ana Ciurea, Sharon Hymes, Denái R. Milton, Kenneth Y. Tsai, Victor G. Prieto, Carlos A. Torres-Cabala, Jonathan L. Curry, BRAF inhibitor therapy–associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression, Human Pathology, 2016, 50, 79

    CrossRef

  2. 2
    Alexander M. Menzies, James S. Wilmott, Martin Drummond, Serigne Lo, Megan Lyle, Matthew M. K. Chan, John F. Thompson, Alex Guminski, Matteo S. Carlino, Richard A. Scolyer, Richard F. Kefford, Georgina V. Long, Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors, Cancer, 2015, 121, 21
  3. 3
    James S Wilmott, Andrew J Colebatch, Hojabr Kakavand, Ping Shang, Matteo S Carlino, John F Thompson, Georgina V Long, Richard A Scolyer, Peter Hersey, Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma, Modern Pathology, 2015, 28, 7, 884

    CrossRef

  4. 4
    Jason Madore, Ricardo E. Vilain, Alexander M. Menzies, Hojabr Kakavand, James S. Wilmott, Jessica Hyman, Jennifer H. Yearley, Richard F. Kefford, John F. Thompson, Georgina V. Long, Peter Hersey, Richard A. Scolyer, PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials, Pigment Cell & Melanoma Research, 2015, 28, 3
  5. 5
    C.J. Rowe, M.H. Law, J.M. Palmer, S. MacGregor, N.K. Hayward, K. Khosrotehrani, Survival outcomes in patients with multiple primary melanomas, Journal of the European Academy of Dermatology and Venereology, 2015, 29, 11
  6. 6
    James S. Wilmott, Matthew A. Field, Peter A. Johansson, Hojabr Kakavand, Ping Shang, Ricardo De Paoli-Iseppi, Ricardo E. Vilain, Gulietta M. Pupo, Varsha Tembe, Valerie Jakrot, Catherine A. Shang, Jonathan Cebon, Mark Shackleton, Anna Fitzgerald, John F. Thompson, Nicholas K. Hayward, Graham J. Mann, Richard A. Scolyer, Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes, Pathology, 2015, 47, 7, 683

    CrossRef

  7. 7
    M S Carlino, L E Haydu, H Kakavand, A M Menzies, A L Hamilton, B Yu, C C Ng, W A Cooper, J F Thompson, R F Kefford, S A O'Toole, R A Scolyer, G V Long, Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma, British Journal of Cancer, 2014, 111, 2, 292

    CrossRef

  8. 8
    A. Vecchiato, S. Pasquali, C. Menin, M.C. Montesco, M. Alaibac, S. Mocellin, L.G. Campana, D. Nitti, C.R. Rossi, Histopathological characteristics of subsequent melanomas in patients with multiple primary melanomas, Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1
  9. 9
    A M Menzies, J S Wilmott, G V Long, R A Scolyer, Intra-patient heterogeneity of BRAF mutation status: fact or fiction?, British Journal of Cancer, 2014, 111, 8, 1678

    CrossRef

  10. 10
    Kimberley L. Kaufman, Swetlana Mactier, Nicola J. Armstrong, Duthika Mallawaaratchy, Scott N. Byrne, Lauren E. Haydu, Valerie Jakrot, John F. Thompson, Graham J. Mann, Richard A. Scolyer, Richard I. Christopherson, Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients, Clinical & Experimental Metastasis, 2014, 31, 4, 407

    CrossRef

  11. 11
    Rajmohan Murali, Richard A. Scolyer, Bruce K. Armstrong, Multiple primary cutaneous melanomas, Pathology, 2013, 45, 1, 1

    CrossRef